Videos

By Prof. Sven Francque

9 June 2022

5Th Global Nash Congress

By Prof. A.G.(Onno) Holleboom

25 May 2022

Going beyond the liver in NAFLD/NASH: hepatologist’s / endocrinologist’s perspective

By Prof. A.G.(Onno) Holleboom

9 May 2022

Getting to the heart of NAFLD/NASH – the CVD perspective

By Prof. Jérôme Boursier

22 April 2022

Non-Invasive Evaluation of NAFLD Severity

By Dr Romero-Gomez

12 April 2022

NIT for screening, referral & diagnosis of NAFLD

By Dr. Maarten E. Tushuizen

4 April 2022

NAFLD/NASH as a metabolic disease: improving patients outcomes

By Prof. Stéfan Darmoni

23 March 2022

Clinical Data Warehouse : definitions and use cases

By Prof. A.G.(Onno) Holleboom

16 March 2022

NAFLD / NASH as a metabolic disease: improving patients outcomes

By Prof. François Dufour

10 March 2022

Cancers and NASH

By Prof. Marat Fudim

24 February 2022

Link between NAFLD and HFpEF

By Dr. Nicolas Lanthier

24 January 2022

Interactions between gut microbiota and PPARs in NAFLD

By Prof. Zelber-Sagi

10 January 2022

Lifestyle treatment for NAFLD in daily practice

By Prof. Robert Chilton

31 December 2021

NASH and CV disease: new considerations

By Dr. Moritz Peiseler

22 December 2021

New insights into the role of inflammation in NAFLD

By Prof. Zelber-Sagi

25 November 2021

Lifestyle prevention & treatment for NAFLD

By Prof. Rautou

16 November 2021

Liver sinusoidal endothelial cell (LSEC) capillarization in NASH

By Dr Romero-Gomez

25 October 2021

The course of liver histology and morbi-mortality in NAFLD / NASH

By Dr Wong and Dr Cusi

11 October 2021

The complex interaction between body weight and NAFLD / NASH

By Prof. Jeffrey V Lazarus

28 September 2021

Defining comprehensive models of care for NAFLD Liver health specialists

By Prof. Bugianesi

9 August 2021

HCC in Patients with NAFLD/NASH

By Prof. Schattenberg

27 July 2021

NASH and quality of life

By Prof. Sanyal

15 July 2021

NASH is part of a multi-system disorder

By Prof. Sven Francque

6 July 2021

From number-one liver disease to multi-system disease: NASH, a major unmet clinical need

By Dr Romero

16 June 2021

Imaging biomarkers in NAFLD: Could they avoid liver biopsy

By Prof. F. Tacke

10 June 2021

Inflammation in NASH and the transition to HCC: an update on scientific breakthroughs by Dr Peiseler and Prof Tacke, Germany

By Prof. F. Tacke

31 May 2021

New insights into liver macrophages in NASH pathogenesis

By Dr. Byrne

31 May 2021

Non-alcoholic fatty liver disease (NAFLD): a multisystem disease – part 2

By Dr. Byrne

11 May 2021

Non-alcoholic fatty liver disease (NAFLD): a multisystem disease – part 1

By Prof. Kenneth Cusi

4 May 2021

Management of non-alcoholic steatohepatitis (NASH): a multiorgan disease driven by insulin resistance, obesity and T2D

By Prof. Sanyal

16 April 2021

Phase 3 development in the field of non-alcoholic steatohepatitis (NASH)

By Prof. Magdy Abdelhamid

15 April 2021

NASH treatment: State of the art in 2020

By Prof. Kenneth Cusi

22 March 2021

Management of Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: Weight gain with PPAR-γ Agonists

By Prof. Kenneth Cusi

8 March 2021

Management of patients with T2D and NAFLD: the role of PPAR-γ

By Prof. Sven Francque

19 February 2021

Nonalcoholic steatohepatitis: the role of PPARs (Peroxisome proliferator-activated receptors)

By Prof. Kenneth Cusi

1 February 2021

Management of patients with Type 2 Diabetes (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD)

By Prof. Sacks

1 December 2020

PPAR gamma agonist

By Prof. Rautou

26 November 2020

Biomarkers in NASH

By Prof. Roden

11 November 2020

PPAR’s as critical regulators of metabolism

By Prof. Sacks

14 October 2020

PPAR alpha delta : what you need to know about the latest results

By Prof. Sacks

8 October 2020

PPAR alpha gamma dual agonists : what you need to know

By Prof. G Rosano

10 September 2020

The prevalence, risks and costs of NASH

By Prof. Roden

22 September 2020

NAFLD and states of insulin resistance

By Prof. Sacks

3 September 2020

Lipids effects of PPARs by Prof. F. Sacks

By Prof. Rautou

28 August 2020

Microvesicles as NAFLD biomarkers: a clinician’s point of view by Prof. P. E. Rautou

By Prof. Sacks

5 August 2020

The link between lipids and PPARs in NASH by Prof. F. Sacks

By Prof. P. Bedossa

22 July 2020

Liver biopsy in NASH by Prof. P. Bedossa

By Prof. F. Tacke

25 June 2020

The multiple risks in NAFLD by Prof. F. Tacke

By Prof. P. Bedossa

10 June 2020

Liver biopsy in NASH clinical trials by Prof. P. Bedossa

By Prof. F. Tacke

27 May 2020

Role of PPARs (experimental paper) by Prof. F. Tacke

By Prof. Sven Francque

21 May 2020

NAFLD: time to update the terminology? By Prof. S. Francque

By Prof. Sven Francque

12 May 2020

NASH and NAFL: it is not only about liver but it is a complex inter-organ crosstalk in which adipose tissue dysfunction is an important driver of the disease.

By Prof. Sven Francque

6 May 2020

NAFLD: a hegemonic disease by Prof. S. Francque

By Prof. Dufour

24 April 2020

PPARs: State-of-the-art by Prof. J.-F. Dufour

By Prof. Sven Francque

16 April 2020

The role of a global holistic approach in NASH management: important messages

By Prof. Kenneth Cusi

8 April 2020

The role of insulin resistance and insulin-sensitizers in NASH management: tips for the practicing clinician

By Prof. Dufour

2 April 2020

The role of comorbidities in NASH management: a holistic approach

By Prof. Rautou

25 March 2020

The role of liver sinusoidal endothelial cells

By Prof. Magdy Abdelhamid

19 March 2020

What can we expect from PPAR agonists in the treatment of NASH?

By Prof. Sancho

11 March 2020

Pre-clinical study with Lanifibranor – Prof Gracia-Sancho

By Prof. Roden

26 February 2020

The role of PPARs in NASH fibrogenesis

By Prof. Szabo

12 February 2020

The role of PPARs in NASH fibrogenesis

By Prof. F. Tacke

5 February 2020

The role of PPARs in inflammation

By Prof. Sven Francque

24 January 2020

Important trials during the Liver meeting in Boston

By Prof. Sancho

20 January 2020

Prof Jordi Gracia-Sancho, Barcelona, discusses the need to develop new therapeutic approaches that target more than one molecular pathway for chronic liver disease.

By Prof. Roden

9 January 2020

Prof Roden highlights the sessions dedicated to obesity and the metabolic syndrom held during the Liver meeting 2019 in Boston

By Prof. Dufour

9 December 2019

Prof Jean-François Dufour highlights why the Liver meeting 2019 in Boston is relevant for NASH investigators with presentations of new modes of action and non-invasive biomarkers.

By Prof. Szabo

5 December 2019

Prof G. Szabo reviews the learnings about alcohol consumption and liver disease that were presented during the Liver meeting 2019 in Boston.

By Prof. F. Tacke

29 November 2019

Prof Tacke explains why he feels the basic science part of the Liver meeting 2019 in Boston was exciting.

By Prof. Kenneth Cusi

25 November 2019

Prof Cusi sheds light on the new exciting information made public at the Liver meeting in Boston

By Prof. Magdy Abdelhamid

25 November 2019

Prof Abdelmalek shares her perspectives about the highlights of the Liver meeting in Boston. She sees a lot of hope in new clinical trials and new biomarkers.

By Prof. Sancho

18 November 2019

Prof Jordi Gracia-Sancho, Barcelona, discusses this important topic in an interview filmed in Boston during the Liver meeting 2019.

By Prof. Dufour

1 November 2019

Prof Dufour discusses best practices about the diagnosis of NASH

By Prof. Kenneth Cusi

13 September 2019

Prof Kenneth Cusi, USA discusses the role of diabetologists in screening for NASH

By Prof. Sven Francque

23 July 2019

Why are PPAR agonists a promising option for the management of NASH ?

By Prof. Kenneth Cusi

3 July 2019

Lipotoxicity in NASH

By Prof. Szabo

24 June 2019

Prof Szabo, USA discusses the progresses of the quest of biomarkers in NASH

By Prof. Magdy Abdelhamid

10 May 2019

An insight into the prevalence of NAFLD and NASH. Prof Abdelmalek, USA

By Prof. Magdy Abdelhamid

10 May 2019

What are the current definitions ? Prof Abdelmalek, USA

By Prof. Sven Francque

10 May 2019

Learn more about the burden of the disease, Prof Sven Francque, Belgium

By Prof. Dufour

9 May 2019

Is NASH only about the liver ?

By Prof. Rautou

16 June 2016

Prof Pierre-Emmanuel Rautou, Paris, France highlights two important abstracts

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.